Search clinical trials for: insulin aspart

Total 4394 results

Novo Nordisk A/S

Completed

A Research Study, Looking at How Ryzodeg® (Insulin Degludec/Insulin Aspart) Works in People With Type 2 Diabetes in Local Clinical Practice (ARISE)

Diabetes Mellitus, Type 2

Malaysia, South Africa, Philippines, Australia, India, Saudi Arabia
Novo Nordisk A/S

Completed

A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

Poland, Croatia, Germany, Turkey, Slovakia, Bulgaria, Romania, Algeria, Czechia, Ukraine
Novo Nordisk A/S

Completed

Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in India

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

India
Novo Nordisk A/S
HNEC TEST

Completed

A Trial Investigating the Total Exposure of NN5401 (Insulin Degludec/Insulin Aspart) in Children, Adolescents and Adult Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Joslin Diabetes Center
Novo Nordisk A/S

Terminated

Glycemic Stability of Insulin Aspart Versus Insulin Lispro in Insulin Pump Therapy

Type 1 Diabetes Mellitus

United States
Tulane University Health Sciences Center

Completed

Comparison of Insulins Aspart and Lispro in Insulin Pumps

Type 1 Diabetes Mellitus

United States
University of Texas Southwestern Medical Center
Novo Nordisk A/S

Withdrawn

Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin (RASCIN)

Type 2 Diabetes

United States
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland, Spain, Sweden, Malaysia, France, Netherlands, India, Argentina, South Africa, Romania, Former Serbia and Montenegro, Austria, Czech Republic, Philippines, Mexico
Novo Nordisk A/S

Terminated

Safety and Efficacy of Inhaled Insulin in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Israel, Italy, United Kingdom, Denmark, Spain, Singapore, Taiwan, Germany, France, Hong Kong, Brazil
University of Florida
Novo Nordisk A/S; VA Office of Research and Development

Completed

Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes

Type 2 Diabetes

United States
Novo Nordisk A/S

Completed

Investigating the Effect of Ryzodeg® in Adult Patients With Type 2 Diabetes in Lebanon

Diabetes Mellitus, Type 2

Lebanon
Sanofi

Completed

Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy (SWITCH)

Type 2 Diabetes Mellitus

China
Novo Nordisk A/S

Completed

A Trial to Test for Bioequivalence Between NN1045 and NN5401 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Medical University of Warsaw

Not yet recruiting

Does the Use of Fiasp vs. Asp Lead to the Prolonged TIR in Children With Type 1 Diabetes?

Diabetes Mellitus, Type 1 | Diabetes type1
Novo Nordisk A/S

Completed

Efficacy and Safety of Insulin Aspart in MDI or CSII in Children Below 7 Years of Age With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Poland
Emory University

Completed

Point-of-Care Glucose Testing and Insulin Supplementation (POC)

Diabetes

United States
Gan and Lee Pharmaceuticals, USA

Enrolling by invitation

A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects With T2DM

Type 2 Diabetes

China
Novo Nordisk A/S

Completed

Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico, Malaysia, Mexico, Turkey, Thailand, Korea, Republic of
Novo Nordisk A/S

Completed

Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, France, Sweden, Poland, Turkey, Korea, Republic of, India, South Africa
Novo Nordisk A/S

Completed

Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes (BEGIN™)

Diabetes | Diabetes Mellitus, Type 1

India, Italy, United Kingdom, Finland, Japan, Argentina, Macedonia, The Former Yugoslav Republic of, Brazil
Novo Nordisk A/S

Completed

Comparison of NN1250 Versus Insulin Detemir, Both Combined With Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
University Hospital, Toulouse

Completed

Efficacy of Continuous Subcutaneous Insulin Infusion Versus Basal-bolus Multiple Daily Injections Regimen in Type 2 Diabetes

Type 2 Diabetes Mellitus

France
Sanofi

Completed

Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine (GEMELLI1)

Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus

Hungary, Russian Federation, Germany, Poland, Japan, United States, Finland
Amphastar Pharmaceuticals, Inc.

Completed

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers

Pharmacokinetics | Pharmacodynamics

United States
Novo Nordisk A/S

Completed

Comparison of Insulin Aspart Produced by the NN2000 Process to the Current Process in Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Poland, Germany, Italy, Hungary, Czech Republic
Novo Nordisk A/S

Completed

Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process

Healthy | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

An Observational Study to Assess Safety and Effectiveness of Intravenous NovoRapid® in Hospitalised Subjects

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

India
Novo Nordisk A/S

Completed

Special Survey for Patients With Type 1 or Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Special Survey for Type 1 or Type 2 Diabetic Patients

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Japan
Sanofi

Terminated

Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting (BASAAL PLUS)

Diabetes Mellitus, Type 2

Netherlands
Novo Nordisk A/S

Completed

Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany, Spain, France, Norway, Romania
Nanjing First Hospital, Nanjing Medical University

Completed

Comparison of Efficacy and Safety of Prandilin and NovoRapid in Newly Diagnosed Type 2 Diabetes

Diabetes Mellitus, Type 2

China
Novo Nordisk A/S

Completed

A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6) (ONWARDS 6)

Diabetes Mellitus, Type 1

United States, India, Italy, Russian Federation, United Kingdom, Canada, Netherlands, Austria, Japan, Spain, Germany, Turkey
Novo Nordisk A/S

Completed

Efficacy and Safety of Insulin Aspart vs. Human Insulin During Pregnancy by Women With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United Kingdom, Denmark, Canada, France, Netherlands, Austria, Israel, Finland, Russian Federation, Croatia, Bulgaria, Poland, Ireland, Spain, Norway, Greece, Argentina, Germany
Novo Nordisk A/S

Completed

Comparison of the Pharmacodynamics and Pharmacokinetics of Insulin Aspart and Human Insulin in Elderly People With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Sanofi

Completed

Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine (GEMELLI X)

Type 1 Diabetes Mellitus

United States
Karolinska Institutet

Terminated

Insulin Infusion Diabetes Ulcer (IINDU)

Hyperglycemia | Diabetes Mellitus | Insulin Resistance | Surgery | Infection | Ulcers

Sweden
Rush University Medical Center
Novo Nordisk A/S

Completed

Management of Diabetes in the Emergency Room: a Randomized Trial of an Insulin Protocol.

Type 2 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

Efficacy and Safety of a Fixed or a Flexible Supplementary Insulin Therapy in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

An Observational Study of Insulin Aspart and, if Necessary, Insulin Levemir (FlexPen®) in the Evening or at Bedtime

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

A Regulatory Post Marketing Surveillance (rPMS) Study of Ryzodeg® FlexTouch® (Insulin Degludec /Insulin Aspart) to Evaluate Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice in Korea

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Korea, Republic of
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4) (ONWARDS 4)

Diabetes Mellitus, Type 2

United States, Japan, Mexico, Russian Federation, Netherlands, Belgium, Italy, India, Romania
Novo Nordisk A/S

Completed

Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes (BEGIN™)

Diabetes | Diabetes Mellitus, Type 1

United States, France, United Kingdom, Russian Federation, Germany, South Africa
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes (BEGIN™)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, United Kingdom, Belgium, Norway, Germany, Greece
Novo Nordisk A/S

Completed

Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Puerto Rico, Spain, Russian Federation, Turkey, Austria, India, Korea, Republic of
Tampere University Hospital

Unknown

Glucose Control During Labour in Gestational Diabetes Mellitus With Insulin Treatment: A Randomized Controlled Trial

Gestational Diabetes | Hypoglycemia, Neonatal

Finland
Novo Nordisk A/S

Completed

Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany, South Africa, Russian Federation, Former Serbia and Montenegro, North Macedonia
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 Diabetes (ADAPT)

Diabetes | Diabetes Mellitus, Type 1

France, Belgium, Luxembourg
Novo Nordisk A/S

Completed

Safety Follow-up on Children and Adolescents With Type 1 Diabetes Treated With Insulin Detemir. An Extension to Trial NN304-1689

Diabetes | Diabetes Mellitus, Type 1

France, Denmark, Finland, Russian Federation, Macedonia, The Former Yugoslav Republic of, Hungary, Bulgaria, United Kingdom, Turkey, Czech Republic, Poland
Yale University
Juvenile Diabetes Research Foundation

Completed

Diluted Insulin in Young Children: Bigger Volumes for Smaller Patients

Type1diabetes

United States

Search clinical trials for: insulin aspart

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations